Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIIB021 + trastuzumab
- Development stage
- Phase 1
- Lead developer
- Biogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (BIIB021), Intravenous (trastuzumab)
01
Overview
BIIB021 + trastuzumab is a combination therapy studied for the treatment of advanced HER2-positive breast cancer. BIIB021 (also known as CNF2024) is an orally available small molecule inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone involved in the stabilization and function of several oncogenic proteins. Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in some breast cancers. The combination aims to inhibit tumor growth by both blocking HER2 signaling and destabilizing multiple client proteins required for cancer cell survival. This combination was evaluated in phase 1 clinical trials to determine safety, pharmacokinetics, and pharmacodynamics in patients with advanced HER2-positive breast cancer[1][2][3].
- Other names
- CNF2024 + trastuzumabBIIB021 + Herceptin
02
Targets
HSP90AA1 (Heat shock protein HSP90-alpha)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on BIIB021 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIIB021 + trastuzumab.